Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, Sasamata M. Nakahara T, et al. Among authors: takeuchi m. Cancer Sci. 2011 Mar;102(3):614-21. doi: 10.1111/j.1349-7006.2010.01834.x. Epub 2011 Jan 12. Cancer Sci. 2011. PMID: 21205082 Free article.
Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Nakamura N, Yamauchi T, Hiramoto M, Yuri M, Naito M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Yokota H, Kawabata S, Furuichi K. Nakamura N, et al. Among authors: takeuchi m. Mol Cell Proteomics. 2012 Jul;11(7):M111.013243. doi: 10.1074/mcp.M111.013243. Epub 2012 Mar 22. Mol Cell Proteomics. 2012. PMID: 22442257 Free PMC article.
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S, Furuichi K. Yamauchi T, et al. Among authors: takeuchi m. Biochem Biophys Res Commun. 2012 Sep 7;425(4):711-6. doi: 10.1016/j.bbrc.2012.07.103. Epub 2012 Jul 27. Biochem Biophys Res Commun. 2012. PMID: 22842455
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S. Tanaka H, et al. Among authors: takeuchi m. Mol Cancer Ther. 2019 Aug;18(8):1366-1373. doi: 10.1158/1535-7163.MCT-18-0976. Epub 2019 May 15. Mol Cancer Ther. 2019. PMID: 31092564
4,351 results